Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma

NCT01920191 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

CNS Tumor, Adult

Interventions

BIOLOGICAL: IMA 950
BIOLOGICAL: Poly ICLC
OTHER: Immunomonitoring

Sponsor

University Hospital, Geneva

Collaborators

[object Object]
[object Object]